Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

@inproceedings{Takeuchi2016EfficacyAS,
  title={Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study},
  author={Tsutomu Takeuchi and Yoshiya Tanaka and Manabu Iwasaki and Hiroaki Ishikura and Satoshi Saeki and Yuichiro Kaneko},
  booktitle={Annals of the rheumatic diseases},
  year={2016}
}
OBJECTIVE To evaluate the efficacy, safety and dose response of a novel oral Janus kinase inhibitor, peficitinib (ASP015K), as monotherapy in Japanese patients with moderate to severe rheumatoid arthritis (RA). METHODS In a 12-week, double-blind study, 281 adult patients with RA with active disease not on concomitant disease-modifying antirheumatic drug therapy were randomised equally to once-daily placebo or peficitinib 25, 50, 100 and 150 mg. The primary endpoint was American College of… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

JAK inhibition in inflammatory bowel disease.

Expert review of clinical immunology • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Pharmacokinetics, safety, and tolerability of ASP015K, a novel Janus kinase inhibitor, in healthy volunteers

T Zhu, T Sawamoto, U Valluri
Ann Rheum Dis • 2013

Similar Papers

Loading similar papers…